ArticleJournal of neuro-oncology2016
Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and/or immunotherapy) in brain metastases: a systematic review.Cancer metastasis reviews · 2021Pooled it
- The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review.International journal of cancer · 2020Pooled it
- Efficacy of BRAF Inhibitors in Combination With Stereotactic Radiosurgery for the Treatment of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Treatment patterns and outcomes in melanoma brain metastasis: exploring immune-related adverse events and survival.Immunotherapy · 2025Article
- A single-center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan.Cancer medicine · 2023Article
- Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.Pigment cell & melanoma research · 2022Review
- Kinase inhibitors increase individual radiation sensitivity in normal cells of cancer patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Targeted therapy strategies for melanoma brain metastasis.Neuro-oncology advances · 2021Article
- Review
- Systemic therapy augmented by radiotherapy (STAR) effect for brain metastases in a BRAF-mutated melanoma patient with prolonged survival: a case report.Radiation oncology journal · 2021Article
- Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis.Melanoma research · 2020Article
- Radiotherapy in combination with systemic therapies for brain metastases: current status and progress.Cancer biology & medicine · 2020Review
- Management of brain metastases according to molecular subtypes.Nature reviews. Neurology · 2020Review
- Review
- Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study.Cancer medicine · 2020Article
- Oligometastasis and local ablation in the era of systemic targeted and immunotherapy.Radiation oncology (London, England) · 2020Review
- Tumor Primary Site and Histology Subtypes Role in Radiotherapeutic Management of Brain Metastases.Frontiers in oncology · 2020Review
- Concurrent Radiosurgery and Systemic Therapies for Melanoma Brain Metastases: A Systematic Review.Cureus · 2019Review
- BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.Neurosurgery · 2019Article
- Emerging findings into molecular mechanism of brain metastasis.Cancer medicine · 2018Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the impact of BRAF inhibitors on survival outcomes in patients receiving stereotactic radiosurgery (SRS) for melanoma brain metastases. We prospectively collected treatment parameters and outcomes for 80 patients with melanoma brain metastases who underwent SRS. Thirty-five patients harbored the BRAF mutation (BRAF-M) and 45 patients did not (BRAF-WT). Univariate and multivariate analyses were performed to identify predictors of overall survival. The median overall survival from first SRS procedure was 6.7, 11.2 months if treated with a BRAF inhibitor and 4.5 months for BRAF-WT. Actuarial survival rates for BRAF-M patients on an inhibitor were 54 % at 6 months and 41 % at 12 months from the time of SRS. In contrast, BRAF-WT had overall survival rates of 28 % at 6 months and 19 % at 12 months. Overall survival was extended for patients on a BRAF inhibitor at or after the first SRS. The median time to intracranial progression was 3.9 months on a BRAF inhibitor and 1.7 months without. The local control rate for all treated tumors was 92.5 %, with no difference based on BRAF status. Patients with higher KPS, fewer treated intracranial metastases, controlled systemic disease, RPA Class 1 and BRAF-M patients had extended overall survival. Overall, patients with BRAF-M treated with both SRS and BRAF inhibitors, at or after SRS, have increased overall survival from the time of SRS. As patients live longer as a result of more effective systemic and local therapies, close surveillance and early management of intracranial disease with SRS will become increasingly important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.